MYC: The Cancer Oncogene’s Surprising Role in Immune Evasion

For decades, the MYC oncogene has been recognized as a key driver of cancer growth, relentlessly promoting cell proliferation. However, recent research reveals a surprising new dimension to MYC’s function: it actively helps cancer cells evade the immune system. This discovery shifts the paradigm of MYC’s role in cancer and opens new avenues for therapeutic intervention.

The Traditional Understanding of MYC

The MYC gene produces the transcription factor Myc, which, when deregulated, fuels uncontrolled cell growth. It achieves this by binding to DNA and activating genes involved in cell cycle progression, metabolism, and protein synthesis . MYC is implicated in the majority of human cancers, though it’s rarely mutated directly; instead, its activity is amplified by other oncogenic signals .

MYC’s Unexpected Role in RNA Quality Control

Recent studies have uncovered an atypical function of the Myc protein. When cancer cells exhibit abnormally high gene activity, leading to unstable DNA, Myc binds to newly synthesized RNA. This interaction forms dense molecular condensates within the nucleus, indicating a function beyond traditional transcriptional regulation .

These condensates don’t promote gene expression; instead, they act as a platform for RNA quality control, eliminating abnormal nucleic acid structures that could trigger an immune response when genes are highly expressed .

Eliminating R-Loops to Evade Immunity

During high gene expression, newly created RNA can sometimes pair with complementary DNA, forming RNA-DNA hybrids called R-loops. If these R-loops aren’t promptly processed or removed, cells recognize them as “abnormal structures” and initiate an immune response. Myc intervenes by binding to RNA and recruiting enzymes that degrade these RNA-DNA hybrids, effectively eliminating the dangerous signals before the immune system can detect them .

Turning Off the Immune Alarm

By eliminating R-loops, Myc prevents activation of the cGAS-STING pathway – a key immune signaling cascade that detects DNA abnormalities. This effectively blinds immune cells, preventing them from identifying cancer cells . Myc uses its RNA-binding function to silence the immune system’s alarm for cancer cells.

Experiments using mutant Myc proteins unable to bind RNA, but still capable of DNA binding, demonstrated that tumors expressing these mutants were more easily cleared by the immune system, confirming the importance of the RNA-binding function for immune evasion.

Implications for Cancer Therapy

MYC has long been considered an “undruggable” target due to its broad physiological functions and the potential for severe side effects with complete inhibition . However, this new understanding of MYC’s role in immune evasion offers a more targeted approach. Instead of completely shutting down MYC, therapies could focus on specifically disrupting its interaction with RNA, thereby restoring the immune system’s ability to recognize and attack cancer cells.

This strategy aims to balance effective cancer control with minimized side effects.

MYC: A Dual-Function Oncogene

The research highlights that MYC is not simply a “throttle” for cell proliferation, but also an “umbrella” protecting cancer cells from immune attack. By controlling RNA quality and removing R-loops, MYC ensures that rapidly proliferating cancer cells remain hidden from the immune system. This combination of rapid growth and immune evasion is what makes cancer cells so challenging to treat.

Further research into MYC’s mechanisms of action promises to unlock new and effective cancer therapies.